Â Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549Â Â FORMÂ 6-KÂ Â REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934Â For the Month of NovemberÂ 2024Â Commission File Number: 001-38097Â Â ARGENX SE(Translation of registrantâ€™s name into English)Â Â Laarderhoogtweg 251101 EB Amsterdam, the Netherlands(Address of principal executive offices)Â Â Indicate by check mark whether the registrant files or will file annualreports under cover of FormÂ 20-F or FormÂ 40-F.Â FormÂ 20-Fâ€¯â€¯â€¯xFormÂ 40-Fâ€¯â€¯â€¯Â¨Â Indicateby check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by Regulation S-T RuleÂ 101(b)(1):Â Â¨Â Indicateby check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by Regulation S-T RuleÂ 101(b)(7):Â Â¨Â Â Â Â Â Â Â EXPLANATORY NOTEÂ On NovemberÂ 20, 2024, argenx SE (the â€œCompanyâ€)issued a press release, a copy of which is attached hereto as ExhibitÂ 99.1 and is incorporated by reference herein.Â The information contained in this Current Reporton FormÂ 6-K, including ExhibitÂ 99.1, shall be deemed to be incorporated by reference into the Companyâ€™s Registration Statementson Forms F-3 (File No.Â 333-258251) and S-8 (File Nos.Â 333-225375,Â 333-258253, and 333-274721), and to be part thereof fromthe date on which this Current Report on FormÂ 6-K is filed, to the extent not superseded by documents or reports subsequently filedor furnished.Â Exhibit Â Description Â Â Â 99.1 Â Press Release NovemberÂ 20, 2024 Â Â Â Â SIGNATURESÂ Pursuant to the requirements of the SecuritiesExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Â ARGENX SE Â Â Â Date: NovemberÂ 20, 2024 By: Â /s/ Hemamalini (Malini) Moorthy Â Â Name: Hemamalini (Malini) Moorthy Â Â Title: General Counsel Â Â Â Â Exhibit 99.1Â argenx Advances Clinical Development of EfgartigimodSC in Idiopathic Inflammatory Myopathies Â -Â Â Phase 2 data establish proof-of-concept of efgartigimod SC in myositisÂ -Â Â Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAÂ -Â Â Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment optionsÂ November 20, 2024, 7:00 AM CET Â Amsterdam, the Netherlands â€“ argenxSE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmunediseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc)in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis), following analysis of toplinedata from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in thestudy, including immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).Â â€œEfgartigimod SC continues to show its promisefor patients suffering from chronic autoimmune diseases,â€ said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. â€œIdiopathicinflammatory myopathies are debilitating diseases that can cause muscle weakness, affect multiple organs, and have a severe impact onpatientsâ€™ quality of life, including increased morbidity and early mortality. We are excited to continue the development of efgartigimodSC across all three subtypes, allowing us to explore the broad potential of this precision therapy for those whose needs remain unmetby current treatments like steroids, plasma-derived therapies, and broad immunosuppressants. We are grateful for the patients and investigatorsparticipating in the ALKIVIA study, and hope to bring efgartigimod to patients living with myositis as soon as possible.â€Â The decision to continue clinical developmentof efgartigimod SC in each of the three myositis subtypes is supported by the efficacy and safety results from the Phase 2 portion ofthe seamless Phase 2/3 ALKIVIA study. Overall, the study met its primary endpoint, demonstrating a statistically significant treatmenteffect in mean total improvement score (TIS) at Week 24, and showed improvement across all six core set measures of the TIS in favor ofefgartigimod SC compared to placebo. The observed safety and tolerability profile was consistent to that demonstrated with other clinicaltrials.Â ALKIVIA Study Design Â The ALKIVIA study isa randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study ofÂ efgartigimod SC for the treatmentof idiopathic inflammatory myopathies (IIM or myositis) across three subtypes, including immune-mediated necrotizing myopathy (IMNM),anti-synthetase syndrome (ASyS), and dermatomyositis (DM). The ALKIVIA study will enroll 240 patients in total and is being conductedin two phases, with an analysis of the PhaseÂ 2 portion of the clinical trial after the first 90 patients completed the study, followedby a PhaseÂ 3 portion if a signal is observed in the PhaseÂ 2 portion. The primary endpoint is the mean total improvement score(TIS) at the end of the treatment period (24 weeks in Phase 2 and 52 weeks in Phase 3) of all treated patients (IMNM, ASyS, DM) comparedto placebo. Key secondary endpoints include response rates at the end of treatment, time to response, and duration of response in TIS,as well as change from baseline in individual TIS components. Other secondary endpoints include quality of life and other functional scores.Â Â Â Â About Idiopathic Inflammatory MyopathiesÂ Idiopathic inflammatorymyopathies (myositis) are a rare group of autoimmune diseases that can be muscle specific or affect multiple organs including the skin,joints, lungs, gastrointestinal tract and heart. Myositis can be very severe and disabling and have a material impact on quality of life.Initially, myositis was classified as either DM or polymyositis, but as the underlying pathophysiology of myositis has become better understood,including through the identification of characteristic autoantibodies, new polymyositis subtypes have emerged. Two of these subtypes areIMNM and ASyS. Proximal muscle weakness is a unifying feature of each subtype. IMNM is characterized by skeletal muscle weakness due tomuscle cell necrosis. ASyS is characterized by muscle inflammation, inflammatory arthritis, interstitial lung disease, thickening andcracking of the hands (â€œmechanicâ€™s handsâ€) and Raynaudâ€™s phenomenon. DM is characterized by muscle inflammationand degeneration and skin abnormalities, including heliotrope rash, Gottronâ€™s papules, erythematous, calcinosis and edema.Â About Efgartigimod SCÂ Efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc)is a human IgG1 antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor(FcRn) and blocking the IgG recycling process. Efgartigimod SC is the first-approved FcRn blocker globally and is marketed as VYVGARTÂ®Hytrulo in the United States and China for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinatingpolyneuropathy (CIDP), and as VYVGART SC or VYVDURA (Japan) for gMG in other regions globally. Efgartigimod SC is currently being evaluatedin more than 15 severe autoimmune diseases where pathogenic IgGs are believed to be mediators of disease.Â About argenxÂ argenx is a global immunology company committedto improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through itsImmunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-basedmedicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan,Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancingseveral earlier stage experimental medicines within its therapeutic franchises. For more information, visit

www.argenx.com andfollow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.Â Media:Â Ben Petokbpetok@argenx.comÂ Â Â Â Investors:Â Alexandra Roy (US)aroy@argenx.comÂ Lynn Elton (EU)lelton@argenx.comÂ Forward Looking StatementsÂ The contents of this announcement include statementsthat are, or may be deemed to be, â€œforward-looking statements.â€ These forward-looking statements can be identified by theuse of forward-looking terminology, including the terms â€œaim,â€ â€œcontinue,â€ â€œhope,â€ â€œpotential,â€or â€œwill,â€ and include statements argenx makes concerning its continued development of efgartigimod SC (efgartigimod alfaand hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study; its plan to continue enrollment of patients across all three myositissubtypes (IMNM, ASyS, DM) under evaluation in the ALKIVIA study; the potential of efgartigimod SC to be the first targeted treatment approachfor myositis patients who have limited other treatment options and whose needs remain unmet by current treatments; its hope to bring efgartigimodto patients living with myositis as soon as possible; its plan for the study design of the ALKIVIA study; and its goal of translatingimmunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involverisks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenxâ€™sactual results may differ materially from those predicted by the forward-looking statements as a result of various important factors,including the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development ofnovel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements in productsand product candidates; the acceptance of argenx's products and product candidates by patients as safe, effective and cost-effective;the impact of governmental laws and regulations on our business; disruptions caused on our reliance of third parties suppliers, serviceprovides and manufacturing; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability andconflicts. A further list and description of these risks, uncertainties and other risks can be found in argenxâ€™s U.S. Securitiesand Exchange Commission (SEC) filings and reports, including in argenxâ€™s most recent annual report on Form 20-F filed with the SECas well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to placeany undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of thisdocument. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-lookingstatements, except as may be required by law.Â Â Â Â